Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1230-1238

  Rosenthal, Eben L ^a   Kulbersh, Brian D ^a   King, Teresa ^a   Chaudhuri, Tandra R ^b   Zinn, Kurt R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CONTRAST MEDIUM; DEOXYRIBONUCLEOTIDE; DYE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROCHROME; IMMUNOGLOBULIN G1;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CONJUGATION; FLUORESCENCE; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; OPERATING ROOM; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SPLIT THICKNESS SKIN GRAFT; SQUAMOUS CELL CARCINOMA; STEREOMICROSCOPY; SURGICAL WOUND; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248173469     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0741     Document Type: Article

References (27)

1. O'Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002; 24:417-22.
2. Ravasz LA, Slootweg PJ, Hordijk GJ, Smit F, van der Tweel I. The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma. J Craniomaxillofac Surg 1991; 19:314-8.
3. Mansfield JR, Gossage KW, Hoyt CC, Levenson RM. Autofluorescence removal, multiplexing, and automated analysis methods for in vivo fluorescence imaging. J Biomed Opt 2005;10:41207.
4. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003;63:7870-5.
5. 3 integrin-targeted optical contrast agents with dynamic optical imaging. J Biomed Opt 2005; 10: 034019.
6. Asgari S, Rohrborn HJ, Engelhorn T, Stolke D. Intra-operative characterization of gliomas by near-infrared spectroscopy: possible association with prognosis. Acta Neurochir (Wien) 2003;145:453-9; discussion 459-60.
7. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63: 8122-5.
8. Nimura H, Narimiya N, Mitsumori N, et al. Infrared ray electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes of patients with gastric cancer. Br J Surg 2004;91: 575-9.
9. Soltesz EG, Kim S, Kim SW, et al. Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann Surg Oncol 2006;13: 386-96.
10. Parungo CP, Ohnishi S, De Grand AM, et al. In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance. Ann Surg Oncol 2004;11:1085-92.
11. Parungo CP, Ohnishi S, Kim SW, et al. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg 2005;129:844-50.
12. Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 2002;29: 45-54.
13. Bonner JA, De Los Santos J, Waksal HW, et al. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002;12:11-20.
14. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1:719-32.
15. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18: 47-53S.
16. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354: 567-78.
18. Cao J, Sato H, Takino T, Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995;270: 801-5.
19. Zhang W, Matrisian LM, Holmeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52.
20. Pezold JC, Zinn K, Talbert MA, Desmond R, Rosenthal EL. Validation of ultrasonography to evaluate murine orthotopic oral cavity tumors. ORL J Otorhinolaryngol Relat Spec 2006;68:159-63.
21. Gurfinkel M, Ke S, Wen X, Li C, Sevick-Muraca EM. Near-infrared fluorescence optical imaging and tomography. Dis Markers 2003;19:107-21.
22. Nida DL, Rahman MS, Carlson KD, Richards-Kortum R, Follen M. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol 2005;99(3 Suppl 1):S89-94.
23. Sokolov K, Aaron J, Hsu B, et al. Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat 2003;2:491-504.
24. Soukos NS, Hamblin MR, Keel S, et al. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 2001;61:4490-6.
25. Gruss CJ, Satyamoorthy K, Berking C, et al. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol 2003;120:683-92.
26. Schechter NR, Yang DJ, Azhdarinia A, et al. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003;14:49-56.
27. DeNardo GL. Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective. Semin Oncol 2005;32: S27-35.